10-Q: Quarterly report
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders' Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to Be Featured With Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update.
Cingulate to Participate in Benzinga All Live Access Event
Cingulate to Attend DCAT Week 2024 in New York City
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Announces Closing of $7.5 Million Public Offering
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed Release
Cingulate Announces Pricing of $7.5 Million Public Offering
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest Into Cingulate Equity at Premium to Market
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform
Cingulate Receives Guidance From FDA on Path Forward for Anxiety Asset CTx-2103 (Buspirone)
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate
Cingulate to Host CNS Key Opinion Leader Panel in New York City
Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR Drug Delivery Platform InnovationsKANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a bi
Cingulate Inc. to Present at the LD Micro Main Event XVI
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Announces Closing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed
Cingulate Announces Pricing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed
Werth Family Investment Associates Converts $5.8 Million of Debt Into Cingulate Equity at a Premium
Conversion Follows $1.0 Million Capital Investment in August 2023KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizin
Cingulate Announces Presentation of Full Trial Results From Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster AwardsKANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Pre
No Data